596.54
price up icon0.37%   2.22
after-market After Hours: 596.54
loading
Regeneron Pharmaceuticals Inc stock is traded at $596.54, with a volume of 666.04K. It is up +0.37% in the last 24 hours and up +5.93% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$594.32
Open:
$588.48
24h Volume:
666.04K
Relative Volume:
0.63
Market Cap:
$63.32B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
15.19
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
+3.63%
1M Performance:
+5.93%
6M Performance:
-19.88%
1Y Performance:
-39.27%
1-Day Range:
Value
$586.68
$598.56
1-Week Range:
Value
$558.45
$598.56
52-Week Range:
Value
$520.50
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,158
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.54 62.15B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ONC
Beigene Ltd Adr
233.37 25.21B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.66 112.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2632 40.72M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.58 5.75B 0 -153.72M -103.81M -2.00

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
12:02 PM

Bankrupt 23andMe sold for $256M—Who owns 15M DNA profiles now? - NewsBytes

12:02 PM
pulisher
May 19, 2025

Genetic data will be safeguarded with 23andMe sale, drugmaker vows - The Washington Post

May 19, 2025
pulisher
May 19, 2025

Pharma giant Regeneron to buy genetics firm 23andMe for $256m - Tech in Asia

May 19, 2025
pulisher
May 19, 2025

Regeneron acquires bankrupt 23andMe for 356 billion won amid data breach fallout - Chosunbiz

May 19, 2025
pulisher
May 19, 2025

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services - HIT Consultant

May 19, 2025
pulisher
May 19, 2025

Regeneron Sees 23andMe Buy As Complement To Genetics PlatformClone - insights.citeline.com

May 19, 2025
pulisher
May 19, 2025

23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts - MedCity News

May 19, 2025
pulisher
May 19, 2025

What's not included in the 23andMe deal, and who else was bidding - The Business Journals

May 19, 2025
pulisher
May 19, 2025

23andMe Finds $256M Buyer in Regeneron After Chapter 11 Filing - Athletech News

May 19, 2025
pulisher
May 19, 2025

Regeneron Acquires 23andMe for $256 Million, Expanding Its Genetic Data and Innovation Footprint - WebProNews

May 19, 2025
pulisher
May 19, 2025

23andMe To Be Acquired By Tarrytown-Based Regeneron For $256M - Patch

May 19, 2025
pulisher
May 19, 2025

Nuveen Asset Management LLC Sells 211,009 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 19, 2025
pulisher
May 19, 2025

Mufg Securities Americas Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 19, 2025
pulisher
May 19, 2025

Now we know who's getting 23andMe's DNA data. Meet Regeneron Pharmaceuticals. - Mashable SEA

May 19, 2025
pulisher
May 19, 2025

23andMe to Be Bought by Biotech Company for $256 Million - The New York Times

May 19, 2025
pulisher
May 19, 2025

Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - USA Today

May 19, 2025
pulisher
May 19, 2025

Biotechnology company Regeneron buying 23andMe for $256 million - The Journal Gazette

May 19, 2025
pulisher
May 19, 2025

Regeneron plans to buy 23andme from bankruptcy for $256M - BioWorld MedTech

May 19, 2025
pulisher
May 19, 2025

Regeneron Pharmaceuticals to buy 23andMe for over $250 million - wng.org

May 19, 2025
pulisher
May 19, 2025

23andMe to be acquired by NY-based Regeneron in $256 million deal - KTVU

May 19, 2025
pulisher
May 19, 2025

23andMe assets being sold to Regeneron Pharma for $256M - MSN

May 19, 2025
pulisher
May 19, 2025

Wachtell-Led Regeneron To Buy 23andMe, Gaining User Data - Law360

May 19, 2025
pulisher
May 19, 2025

23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction - Investor's Business Daily

May 19, 2025
pulisher
May 19, 2025

Bankrupt 23andMe Just Sold Off All Your DNA Data - futurism.com

May 19, 2025
pulisher
May 19, 2025

Why Regeneron is buying 23andMe - Endpoints News

May 19, 2025
pulisher
May 19, 2025

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - Benzinga

May 19, 2025
pulisher
May 19, 2025

Focus Partners Wealth Purchases 6,213 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

May 19, 2025
pulisher
May 19, 2025

Struggling DNA testing firm 23andMe to be bought for $256m - BBC

May 19, 2025
pulisher
May 19, 2025

Regeneron Pharmaceuticals to buy 23andMe for $256M - ABC News

May 19, 2025
pulisher
May 19, 2025

Regeneron in $256M deal to acquire human genetics and bio company - Westfair Communications

May 19, 2025
pulisher
May 19, 2025

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data - Reuters

May 19, 2025
pulisher
May 19, 2025

Bankrupt DNA testing company 23andMe to be bought by Regeneron - CBC

May 19, 2025
pulisher
May 19, 2025

Regeneron to acquire 23andMe DNA testing firm. How that could impact your genetic data - Lohud

May 19, 2025
pulisher
May 19, 2025

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data | Business Information & News | FE - Westlaw Today

May 19, 2025
pulisher
May 19, 2025

From $6 Billion to Bankruptcy: The Fall and Sale of 23andMe to Regeneron - FXLeaders

May 19, 2025
pulisher
May 19, 2025

Regeneron agrees to buy bankrupt 23andMe - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Bankrupt 23andMe Expected to Be Purchased for $256M - People.com

May 19, 2025
pulisher
May 19, 2025

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million - WSJ

May 19, 2025
pulisher
May 19, 2025

Regeneron Win Underscores Importance of Simple Market Definition - Bloomberg Law News

May 19, 2025
pulisher
May 19, 2025

Regeneron to buy bankrupt DNA testing company 23andMe for $256 million - Mezha.Media

May 19, 2025
pulisher
May 19, 2025

23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction - Gizmodo

May 19, 2025
pulisher
May 19, 2025

Doubling down on genetics-guided drug development, Regeneron to buy 23andMe - FirstWord Pharma

May 19, 2025
pulisher
May 19, 2025

Regeneron to Acquire 23andMe with Winning $256M Bid - Genetic Engineering and Biotechnology News

May 19, 2025
pulisher
May 19, 2025

OraSure stock rises following Regeneron’s 23andMe acquisition - Investing.com

May 19, 2025
pulisher
May 19, 2025

Regeneron Buys 23andMe in Bankruptcy Auction - Investopedia

May 19, 2025
pulisher
May 19, 2025

Regeneron to buy bankrupt DNA testing company 23andMe for $256M - NewsNation

May 19, 2025
pulisher
May 19, 2025

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions - New York Post

May 19, 2025
pulisher
May 19, 2025

OraSure rises as seen benefitting from 23andMe/Regeneron deal - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

Regeneron to buy 23andMe out of bankruptcy for $256 mn - Medical Xpress

May 19, 2025
pulisher
May 19, 2025

Regeneron Pharmaceuticals Picks Up 23andMe Assets In Bankruptcy Auction - Finimize

May 19, 2025
pulisher
May 19, 2025

Regeneron buys bankrupt 23andMe for $256m - Yahoo Finance

May 19, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.58
price up icon 1.78%
$1.2632
price down icon 0.54%
$291.86
price up icon 2.30%
$4.0532
price up icon 1.58%
$32.99
price up icon 6.66%
Cap:     |  Volume (24h):